Digestive system cancers represent a group of malignancies with high global incidence and a particularly heavy disease burden in China. Among these, gastric cancer, colorectal cancer, and biliary tract cancer represent critical human epidermal growth factor receptor 2 (HER2)-positive subtypes that require focused clinical attention. Antibody–drug conjugates (ADCs), which utilize HER2-targeted monoclonal antibodies to deliver cytotoxic agents directly to tumor cells, have revolutionized precision therapy in HER2-positive cancers, marking a significant milestone in oncologic treatment. Currently, trastuzumab deruxtecan and disitamab vedotin have been approved for the treatment of advanced gastric cancer. This expert consensus emphasizes the safety management of HER2 ADCs in digestive system cancers, considering the unique anatomical complexity and the vulnerability of the mucosal barrier in this system. It underscores the essential role of multidisciplinary team collaboration in standardizing the management of adverse events and offers evidence-based recommendations to guide clinical practice across primary and secondary care settings. Furthermore, it underscores the value of a “physician-led, patient-engaged” model in patient education. The safety management experience accumulated in this context also offers important insights for the clinical application of ADCs targeting other oncogenic pathways.

Robot surgery is an important trend in contemporary colorectal cancer surgical treatment. The Robotic Surgery Group, Colorectal Cancer Committee of Chinese Medical Doctor Association organized experts in relevant fields across the country to update and revise the application standards of robotic colorectal cancer surgery based on the Expert consensus on robotic surgery for colorectal cancer (2015 edition) and the revised version in 2020, in accordance with the development of robotic surgery concepts, technologies, and equipment in recent years, in order to promote the application and promotion of robotic surgery.

Ultrasound-guided percutaneous lung needle biopsy (US-PLNB) is a pivotal diagnostic technique for subpleural pulmonary lesions, offering significant advantages including real-time imaging, absence of ionizing radiation, and high procedural flexibility. A multidisciplinary expert panel was convened by more than 10 authoritative Chinese academic societies, including the Chinese Society of Ultrasound in Medicine, to standardize the clinical application of US-PLNB and enhance both procedural safety and diagnostic accuracy. Subsequently, the panel developed the “Chinese expert consensus on ultrasound-guided percutaneous lung needle biopsy (2025 edition),” based on the latest domestic and international evidence-based research. This consensus comprehensively outlines the indications and contraindications, pre-procedural assessment and preparation, intraoperative techniques, complication prevention and management, and post-procedural care related to US-PLNB. Moreover, it presents 18 specific evidence-based recommendations. The consensus aims to provide radiologists and clinicians with standardized procedural guidance, promote the standardized implementation of US-PLNB in clinical practice, and ultimately improve patient care for individuals with pulmonary diseases.

Eyelid tumors, particularly sebaceous carcinoma and meibomian gland carcinoma (MGC), are rare but highly aggressive malignancies characterized by diagnostic difficulty, early dissemination, and limited therapeutic options. Progress in understanding their biology and developing effective treatments has been hampered by the scarcity of robust, patient-derived preclinical models. Conditional reprogramming (CR) technology, which combines Rho-associated kinase (ROCK) inhibition with feeder fibroblast co-culture, enables rapid and reversible expansion of primary epithelial cells while preserving their genetic stability and lineage-specific phenotypic. Over the past decade, CR has emerged as a powerful platform for cancer modeling, drug sensitivity testing, and mechanistic studies across multiple epithelial malignancies. However, its application in ocular oncology remains underexplored. This review summarizes the biological principles and technical features of CR technology, highlights its established applications in epithelial cancer research, and focuses on its emerging relevance to eyelid tumors, particularly MGC. We further address current challenges, including tissue acquisition, standardization and reconstruction of the tumor microenvironment, and the future perspectives integrating CR with organoid culture, multi-omics profiling, and artificial intelligence-based analyses to advance functional precision oncology in eyelid malignancies.